Ameriprise’s Caris Life Sciences CAI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.3M Sell
408,079
-1,097,001
-73% -$24M ﹤0.01% 2175
2025
Q4
$40.6M Sell
1,505,080
-174,388
-10% -$4.91M 0.01% 990
2025
Q3
$50.8M Buy
1,679,468
+53,754
+3% +$1.71M 0.01% 869
2025
Q2
$43.4M Buy
+1,625,714
New +$43.8M 0.01% 935

Other funds holding CAI

Ameriprise's CAI Position: Q1 2026 in Review

Ameriprise reduced its Caris Life Sciences (CAI) stake by 73% in Q1 2026, selling an estimated $24M and leaving 408,079 shares worth $7.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2175.

Ameriprise first reported a position in CAI in Q2 2025 and has held it in 4 quarters since. The position peaked at $50.8M in Q3 2025. 202 funds tracked by Wall St. Rank hold CAI as of Q1 2026.

  • Ameriprise held 408,079 shares of Caris Life Sciences worth $7.3M as of Q1 2026.
  • Ameriprise sold 1,097,001 Caris Life Sciences shares in Q1 2026, an estimated $24M.
  • Caris Life Sciences made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #2175 holding.
  • Ameriprise first reported a position in Caris Life Sciences in Q2 2025 and has held it in 4 quarters since.
  • Ameriprise's Caris Life Sciences position peaked at $50.8M in Q3 2025.
  • 202 funds tracked by Wall St. Rank held Caris Life Sciences as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.